Key Developments: Getinge AB (GETIb.ST)

GETIb.ST on Stockholm Stock Exchange

178.60SEK
9:05am EST
Change (% chg)

-4.60kr (-2.51%)
Prev Close
183.20kr
Open
183.00kr
Day's High
183.90kr
Day's Low
177.70kr
Volume
335,009
Avg. Vol
687,411
52-wk High
236.20kr
52-wk Low
177.70kr

Search Stocks

Latest Key Developments (Source: Significant Developments)

Getinge Group names Pernille Fabricius as new CFO
Tuesday, 22 Dec 2015 07:00am EST 

Getinge AB:Says Pernille Fabricius appointed new CFO of Getinge Group.Fabricius will assume her new position as CFO of Getinge Group on February 22, 2016.  Full Article

Getinge AB says buys Stericool
Monday, 14 Dec 2015 11:15am EST 

Getinge AB:Says Getinge Infection Control enters into low temperature market with acquisition of Stericool and exclusive distribution agreement with TSO3.Says Stericool has its headquarters and manufacturing site in Ankara, Turkey, with a total of 20 employees.Says consolidation of Stericool into Getinge Group will take place from Jan. 1, 2016.Says net sales in 2016 is estimated at 25 million Swedish crowns and EBITDA is expected at 4.5 million crowns.  Full Article

Getinge gives FY 2016 - FY 2019 outlook
Wednesday, 2 Sep 2015 06:24am EDT 

Getinge AB:Says targets annual EBITA improvement of >10 pct.Says targets are for FY 2016 - FY 2019 period.Says outlook for FY 2015 remains unchanged.Expects to achieve EBITA improvement of SEK 2.5-3 billion by FY 2019.Targets annual organic sales growth of 2-4 pct.Says aim is for dividend to correspond to 30-50 pct of net income.  Full Article

Getinge AB proposes dividend of 2.80 swedish crowns
Thursday, 19 Feb 2015 06:26am EST 

Getinge AB:Proposes dividend of 2.80 swedish crowns per share.Payable on April 1.Record date as of March 27.  Full Article

Getinge AB reaches FDA agreement, will hit 2015 earnings
Wednesday, 4 Feb 2015 12:30am EST 

Getinge AB:Medical systems business area reaches agreement concerning consent decree with U.S. Food and Drug Administration.The overall financial impact, excluding the remediation costs, related to the Consent Decree is estimated to amount to 500 million Swedish crowns and will have a negative impact on the operating profit for 2015.The amount includes an initial payment of 48 million crowns to the U.S. Government and also covers loss of revenue as a consequence of temporary unavailability of products, training and education of staff and investment in customer relations.Not covered in the 500 million crowns is the possibility of an additional payment of 48 million crowns if certain milestones in the enhancement program at Atrium's Hudson, New Hampshire facilities are not completed within six months of the first payment.The agreement establishes a framework that provides assurances to FDA that Medical Systems will complete the improvements currently underway to strengthen its quality management system.Under the terms of the Consent Decree, certain products manufactured at Medical Systems' Atrium Medical Corporation business unit will be temporarily suspended while corrections are being made.These products will be temporarily unavailable, once existing inventory located at Medical Systems' distribution facilities has been exhausted.  Full Article

Getinge AB proposes 2014 dividend at SEK 4.15/shr
Wednesday, 28 Jan 2015 07:15am EST 

Getinge AB:Says a dividend per share of 4.15 Swedish crowns is proposed for 2014.Previously proposed a dividend per share of 4.15 crowns for 2013.  Full Article

Getinge AB appoints Alex Myers as new CEO
Monday, 12 Jan 2015 07:08am EST 

Getinge AB:Has decided to appoint Alex Myers as new President and CEO of the Getinge Group.Alex Myers will succeed Johan Malmquist, who has informed the board of directors that he wants to resign from his assignment.Alex Myers will assume his new position in connection with the Annual General Meeting on March 25, 2015.  Full Article

Getinge AB lowers FY 2014 financial outlook
Thursday, 16 Oct 2014 02:00am EDT 

Getinge AB:Posted a Q3 2014 core profit below analyst forecasts.Says earnings before interest, taxes, amortisation and restructuring costs rose to 920 million Swedish crowns (128 million) from a year-earlier 907 million crowns.Says it is anticipated that the organic invoicing growth will fall somewhat short of the volume forecast stated in the six-month report.Says previous forecast was for like-for-like sales to grow around 4 percent in FY 2014.  Full Article

Pulsion Medical Systems SE and indirect subsidiary of Getinge AB, MAQUET, to enter into domination and profit and loss transfer agreement
Thursday, 3 Jul 2014 02:38pm EDT 

Pulsion Medical Systems SE:Says administrative board of Pulsion Medical Systems SE approved the conclusion of a domination and profit and loss transfer agreement between Pulsion Medical Systems SE as controlled entity and MAQUET Medical Systems AG (indirect subsidiary of Getinge AB, Sweden) as controlling entity.MAQUET Medical Systems AG owns 78.26 pct of shares of Pulsion Medical Systems.MAQUET Medical Systems AG offers to acquire shares of minority shareholders of Pulsion Medical Systems SE for cash compensation in amount of 17.03 euros per share.Domination and profit and loss transfer agreement also provides for annual recurring compensation payment in gross amount of 1.02 euros (0.86 euros net based on current taxation) per share.  Full Article

Getinge AB issues Q1 2014 profit outlook below analysts' estimates
Friday, 7 Mar 2014 02:10am EST 

Getinge AB:Says it estimates that Getinge‚Äôs pretax profit for the first quarter of 2014 will amount to about 160 mln Swedish crowns.Q1 2014 pre-tax profit 649.08 mln Swedish crowns - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Getinge CEO: sees 2016 sales growth in line with 2016-19 target, EBITA growth below

* CEO says sees 2016 topline growth within range of company target of 2-4 pct annual organic sales growth for 2016-2019

Search Stocks